Gland Pharma Ltd stock (INE025W01027): record FY26 results, strong US growth and dividend proposal

Gland Pharma has reported record FY26 revenue, sharply higher profit and a proposed final dividend, with momentum in US generics and contract manufacturing drawing investor attention to the India-listed injectables specialist.

Indian injectables maker Gland Pharma Ltd has reported record revenue and sharply higher profit for its fiscal year ended March 31, 2026, alongside a proposed final dividend, putting the Hyderabad-based company on the radar of global and US-focused investors, according to the company’s FY26 results release dated May 15, 2026 and related market reports from the same day NSE India as of 05/15/2026 and MarketScreener as of 05/15/2026.

As of: 05/16/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gland Pharma
• Sector/industry: Pharmaceuticals, injectable generics and contract manufacturing
• Headquarters/country: Hyderabad, India
• Core markets: United States, India and other regulated export markets
• Key revenue drivers: Sterile injectable generics, contract development and manufacturing (CDMO) services
• Home exchange/listing venue: National Stock Exchange of India and BSE (ticker: GLAND)
• Trading currency: Indian rupee (INR)

Gland Pharma Ltd: core business model

Gland Pharma Ltd operates as a specialty pharmaceuticals company focused on sterile injectable products and related contract development and manufacturing services. The company develops and manufactures small-volume parenterals and other injectable formulations that are supplied to global markets, including the United States, according to its corporate profile and FY26 results documentation released on May 15, 2026 NSE India as of 05/15/2026.

The company’s model combines its own portfolio of injectable generics with contract manufacturing for third-party clients. In its FY26 commentary, management highlighted strong performance from contract development and manufacturing (CDMO) activities, which contributed meaningfully to revenue expansion over the year and supported operating leverage in its manufacturing network, according to the May 15, 2026 discussion of results summarized by TradingView’s news feed TradingView as of 05/15/2026.

Gland Pharma’s facilities are focused on sterile manufacturing, a segment that requires tight quality, regulatory and compliance standards. The company supplies to regulated markets such as the United States, where its products must meet US Food and Drug Administration quality expectations, as well as to other international jurisdictions and its home market in India. This positioning allows the business to leverage India-based cost structures while serving higher value markets abroad, according to company descriptions and FY26 disclosures published on May 15, 2026 Gland Pharma investor relations as of 05/15/2026.

The FY26 earnings call transcript from May 15, 2026 shows management emphasizing a strategy that balances product launches with expansion in CDMO relationships. Executives noted the goal of deepening partnerships with large global pharmaceutical companies while continuing to build out a broader portfolio across therapeutic categories and dosage forms within injectables, according to the call prepared remarks and Q&A exchange GuruFocus as of 05/15/2026.

Main revenue and product drivers for Gland Pharma Ltd

For the fiscal year ended March 31, 2026, Gland Pharma reported record consolidated revenue, supported by both its US-focused injectables franchise and its CDMO operations. The company’s FY26 press release cited strong US and contract manufacturing momentum as key drivers of growth and indicated that adjusted EBITDA margin reached about 26%, while adjusted profit after tax grew around 50% year over year, according to the May 15, 2026 filing and associated news coverage NSE India as of 05/15/2026.

In the fiscal fourth quarter of 2026, attributable consolidated profit almost doubled to roughly 3.67 billion Indian rupees from about 1.87 billion rupees a year earlier, with earnings per share rising to approximately 22.23 rupees from 11.34 rupees in the prior-year period, according to a report published on May 15, 2026 MarketScreener as of 05/15/2026. Revenue growth in the quarter reflected ongoing normalization in injectables demand, steady order flows from existing clients, and contributions from new launches.

The company highlighted that US market performance was a key contributor to the full-year results. Management described robust demand for certain anti-infective and hospital products and cited increasing utilization of its manufacturing capacity for US-bound supplies. At the same time, CDMO revenue grew as Gland Pharma expanded collaborations with global pharmaceutical companies. The CDMO segment benefits from multi-year contracts and can add resilience to revenue across product cycles, according to commentary in the FY26 press release and earnings call of May 15, 2026 TradingView as of 05/15/2026.

Profitability benefited from scale and product mix. The adjusted EBITDA margin of around 26% for FY26, as indicated in the May 15, 2026 reporting, reflects operating leverage achieved as revenue increased and as higher-margin contract work and select complex generics contributed a greater share of the portfolio. Management pointed out that ongoing efficiency measures and disciplined cost control also aided margin expansion, although they cautioned that input prices, regulatory requirements and competitive intensity remain important variables going forward, according to the FY26 call transcript released May 15, 2026 GuruFocus as of 05/15/2026.

Alongside results, the board of Gland Pharma recommended a final dividend of 20 Indian rupees per equity share for FY26, subject to shareholder approval at the annual general meeting. The proposed dividend was disclosed in the FY26 results press release filed with the National Stock Exchange of India on May 15, 2026 and reflects the company’s policy of returning cash to shareholders while funding capital expenditure for capacity expansion and development projects NSE India as of 05/15/2026.

On the trading side, Gland Pharma shares closed at about 1,861 Indian rupees on the BSE on May 15, 2026, down roughly 1.8% on the session according to Indian market data cited by a live pricing service that day Tickertape as of 05/15/2026. Over the preceding week, the stock showed a small negative return of around 0.27%, highlighting how share prices can move differently from earnings trends in the short term.

Industry trends and competitive position

Gland Pharma operates in the global injectable generics and CDMO space, which has seen sustained demand from hospital and specialty care segments. The company’s FY26 commentary notes that US injectable markets are competitive but continue to offer opportunities for players able to supply reliably and at scale, especially in molecules where supply shortages or consolidation among manufacturers have occurred in past years, according to the May 15, 2026 results discussion TradingView as of 05/15/2026.

In injectables, regulatory compliance and manufacturing reliability are critical differentiators. Gland Pharma’s facilities cater to regulated markets and must pass routine inspections by authorities such as the US Food and Drug Administration. The company’s ability to secure and maintain approvals is central to its competitive positioning. While the FY26 documents highlight strong operational execution, they also imply that compliance costs and potential inspection outcomes are ongoing factors that investors monitor closely, according to disclosures and management comments dated May 15, 2026 NSE India as of 05/15/2026.

The CDMO business exposes Gland Pharma to a somewhat different competitive set, including global contract manufacturers and integrated pharmaceutical companies offering development and manufacturing services. Management’s FY26 remarks describe CDMO momentum as a pillar of growth, supported by repeat business from multinational partners. This business can deepen relationships with large pharma clients and provide visibility through longer-term agreements, while also requiring continued investment in capacity, quality systems and technical capabilities to match evolving client needs, according to the earnings call and press release of May 15, 2026 GuruFocus as of 05/15/2026.

Why Gland Pharma Ltd matters for US investors

Although Gland Pharma is listed in India, its business has a significant connection to the United States through its sales of injectable generics and its CDMO partnerships with global pharmaceutical companies. The FY26 reporting specifically cites strong US performance as a driver of record revenue and profit growth, underlining the importance of US hospital and specialty markets for the company’s financial profile, according to the May 15, 2026 press release and earnings commentary TradingView as of 05/15/2026.

For US investors with access to Indian equities or global pharmaceutical supply chain themes, Gland Pharma provides exposure to sterile injectable manufacturing located in India but serving developed markets. The company’s performance can be influenced by factors such as US generic pricing, hospital purchasing trends, regulatory developments and supply-demand dynamics in injectable drugs, all of which are relevant topics in the broader US healthcare and pharmaceutical landscape, according to management’s FY26 discussion on May 15, 2026 Gland Pharma investor relations as of 05/15/2026.

Investors based in the US who follow international pharmaceutical manufacturers may also look at Gland Pharma as part of a wider view on outsourcing and globalization in drug production. The company’s CDMO contracts with large pharmaceutical firms and its focus on quality-compliant injectables illustrate how Indian manufacturing capacity continues to integrate into global supply chains. However, such investors typically need to consider currency movements, local market regulations and differences in disclosure practices when assessing India-listed shares.

Conclusion

Gland Pharma Ltd has reported a strong set of FY26 numbers, with record revenue, roughly 50% year-on-year growth in adjusted profit after tax, and an adjusted EBITDA margin near 26%, supported by performance in the United States and expanding CDMO activities, according to filings and news coverage dated May 15, 2026. The board’s proposal of a 20-rupee per share final dividend signals confidence in the balance between shareholder returns and investment in capacity and development. At the same time, investors will continue to track how competitive pressures in injectable generics, regulatory compliance demands and broader macroeconomic factors influence the company’s margins and growth trajectory in coming periods.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.